WallStreetZenWallStreetZen

NASDAQ: KTTA
Pasithea Therapeutics Corp Stock

$0.43+0.01 (+2.38%)
Updated Mar 21, 2023
KTTA Price
$0.43
Fair Value Price
N/A
Market Cap
$12.66M
52 Week Low
$0.40
52 Week High
$1.54
P/E
-1.88x
P/B
0.27x
P/S
128.21x
PEG
N/A
Dividend Yield
N/A
Revenue
$260.91k
Earnings
-$8.19M
Gross Margin
49.5%
Operating Margin
-3,138.5%
Profit Margin
-3,138.5%
Debt to Equity
0.06
Operating Cash Flow
-$12M
Beta
0.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

KTTA Overview

Pasithea Therapeutics Corporation is a biotech company developing treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics was incorporated in 2020 and is headquartered in Miami Beach, FL.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KTTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KTTA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KTTA is good value based on its book value relative to its share price (0.27x), compared to the US Biotechnology industry average (4.85x)
P/B vs Industry Valuation
KTTA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more KTTA due diligence checks available for Premium users.

Be the first to know about important KTTA news, forecast changes, insider trades & much more!

KTTA News

Valuation

KTTA fair value

Fair Value of KTTA stock based on Discounted Cash Flow (DCF)
Price
$0.43
Fair Value
$2.24
Undervalued by
80.77%
KTTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KTTA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.88x
Industry
16.62x
Market
22.45x

KTTA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.27x
Industry
4.85x
KTTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KTTA's financial health

Profit margin

Revenue
$218.6k
Net Income
-$4.6M
Profit Margin
-2,097.9%
KTTA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
KTTA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$49.6M
Liabilities
$2.8M
Debt to equity
0.06
KTTA's short-term assets ($44.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KTTA's short-term assets ($44.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KTTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$5.2M
Investing
-$230.4k
Financing
$0.0
KTTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KTTA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
KTTA$12.66M+2.61%-1.88x0.27x
LIXT$12.80M+13.09%-1.67x2.00x
UPC$12.85M+0.17%-1.48x0.28x
AEZS$12.92M+1.14%-1.04x0.26x
ANPC$12.40M-8.12%-0.45x-25.91x

Pasithea Therapeutics Stock FAQ

What is Pasithea Therapeutics's quote symbol?

NASDAQ: KTTA) Pasithea Therapeutics trades on the NASDAQ under the ticker symbol KTTA. Pasithea Therapeutics stock quotes can also be displayed as NASDAQ: KTTA.

If you're new to stock investing, here's how to buy Pasithea Therapeutics stock.

What is the 52 week high and low for Pasithea Therapeutics (NASDAQ: KTTA)?

(NASDAQ: KTTA) Pasithea Therapeutics's 52-week high was $1.54, and its 52-week low was $0.40. It is currently -71.88% from its 52-week high and 8.52% from its 52-week low.

How much is Pasithea Therapeutics stock worth today?

(NASDAQ: KTTA) Pasithea Therapeutics currently has 29,248,688 outstanding shares. With Pasithea Therapeutics stock trading at $0.43 per share, the total value of Pasithea Therapeutics stock (market capitalization) is $12.66M.

Pasithea Therapeutics stock was originally listed at a price of $3.56 in Sep 15, 2021. If you had invested in Pasithea Therapeutics stock at $3.56, your return over the last 1 years would have been -87.84%, for an annualized return of -87.84% (not including any dividends or dividend reinvestments).

How much is Pasithea Therapeutics's stock price per share?

(NASDAQ: KTTA) Pasithea Therapeutics stock price per share is $0.43 today (as of Mar 21, 2023).

What is Pasithea Therapeutics's Market Cap?

(NASDAQ: KTTA) Pasithea Therapeutics's market cap is $12.66M, as of Mar 22, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Pasithea Therapeutics's market cap is calculated by multiplying KTTA's current stock price of $0.43 by KTTA's total outstanding shares of 29,248,688.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.